← Issue №4/ week of Jul 26, 2026/Endoscopy

A Practical Endoscopic Treatment Strategy for Appendiceal Orifice Lesions Using Forceps-Assisted Polypectomy (Strip Biopsy).

From GI Signals issue №4: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Endoscopy retrospective · n=22 · Jul 25, 2026 · Dig Dis Sci · IF 2.5

A Practical Endoscopic Treatment Strategy for Appendiceal Orifice Lesions Using Forceps-Assisted Polypectomy (Strip Biopsy).

New evidencepolypectomyESD
Clinical takeawayConsider strip biopsy for small appendiceal orifice lesions without malignant features, as it offers faster resection with comparable safety to ESD in this study, but be aware of higher margin positivity (50% vs. 13%).
What it foundForceps-assisted polypectomy (strip biopsy) for carefully selected small appendiceal orifice lesions without malignant features achieved 93% en bloc resection vs. 100% with ESD, with significantly shorter procedure time (6.6 vs. 45.9 min) and no perforations, but had higher margin positivity (50% vs. 13%).
ContextChallenges current overtreatment with ESD for small lesions, offering a simpler alternative with similar short-term outcomes but higher margin positivity.
Measured against the standard of care· USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement)

Decision at stakethe choice of endoscopic resection technique for appendiceal orifice lesions

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

General post-polypectomy surveillance still follows USMSTF 2020 (Gupta et al.), which has not been replaced: 1-2 tubular adenomas <10 mm, 7-10 years; 3-4 tubular adenomas <10 mm, 3-5 years; 5-10 tubular adenomas <10 mm, any adenoma ≥10 mm, or an adenoma with tubulovillous/villous histology or high-grade dysplasia, 3 years; >10 adenomas, 1 year with polyposis evaluation. For serrated polyps: 1-2 SSLs <10 mm, 5-10 years; 3-4 SSLs <10 mm or a hyperplastic polyp ≥10 mm, 3-5 years; an SSL ≥10 mm, an SSL with dysplasia, or a traditional serrated adenoma, 3 years. When findings are mixed, use the shortest interval indicated. Before applying an interval, confirm complete resection and adequate prep. Piecemeal resections get a site check, and malignant (T1) polyps go to a tumor-board pathway. Serrated polyposis syndrome (SPS) is now governed by a separate USMSTF consensus statement (Rex et al., published simultaneously in Gastroenterology, Am J Gastroenterol and GIE on 2026-09-30). It has 11 recommendations. Diagnose SPS with the 2019 WHO criteria, which count the size, cumulative lifetime number and location of serrated polyps. Until SPS is diagnosed, record the number, size and location of serrated polyps in every colonoscopy report. SPS colonoscopy should be done by endoscopists with documented adequate SSL detection, using high-definition white light with or without chromoendoscopy. Without concurrent CRC, endoscopy is preferred over surgery for primary management. If the polyp burden cannot be managed endoscopically, refer to an advanced endoscopic resection expert before surgery. Resect SSLs and hyperplastic polyps by cold snare, with submucosal injection for larger lesions. Do clearance colonoscopy at 3-6 months, then surveil every 1-2 years. Consider 3-year intervals if the burden is greatly reduced at surveillance. First-degree relatives start colonoscopy at age 40, or 10 years before the youngest CRC diagnosis in the family, or 5 years before the youngest SPS diagnosis, whichever comes first. SPS has no established genetic basis, so germline testing is recommended only when concurrent non-serrated polyps suggest a heritable syndrome. Lynch, FAP/AFAP and MAP criteria still trigger genetic evaluation.

USMSTF 2020 (Gupta et al., post-polypectomy surveillance) / USMSTF 2026 (Rex et al., Serrated Polyposis Syndrome consensus statement) · reviewed 2026-10-11 ↗
Iida T … Chiba H · Digestive Diseases and Sciences · IF 2.5 · PubMed ↗Permalink
← Read the whole of issue №4 Every paper GI Signals surfaces gets a page like this one. All issues